<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02942251</url>
  </required_header>
  <id_info>
    <org_study_id>Pending</org_study_id>
    <nct_id>NCT02942251</nct_id>
  </id_info>
  <brief_title>Relapse Predicting Model for First Episode Depression</brief_title>
  <acronym>RPM-FED</acronym>
  <official_title>The Study of Relapse Predicting Model for First Episode Depression: Big Data Analysis Based on Clinical Features and Immunochemistry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Mental Health Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Mental Health Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Major depressive depression(MDD) is an severe public mental disorders. The purpose of current&#xD;
      study is using big data analysis based on clinical features and immunochemistry to&#xD;
      investigate and establish an relapse predict model for patients with first episode MDD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Major depressive depression(MDD) is an severe public mental disorders. The purpose of current&#xD;
      study is using big data analysis based on clinical features and immunochemistry to&#xD;
      investigate and establish an relapse predict model for patients with first episode MDD.&#xD;
&#xD;
      This study includes two steps. Step 1: Big data analysis based on the clinical features and&#xD;
      immunochemical figures of 30000 patients with first episode MDD will be conducted to&#xD;
      construct a relapse predict model.&#xD;
&#xD;
      Step 2: 300 patients with first episode MDD will be recruited in this step. Physicians prefer&#xD;
      to give corresponding treatment recommendation based on the predictive factors to verify this&#xD;
      relapse model.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HAM-D total score</measure>
    <time_frame>12 weeks</time_frame>
    <description>The change from baseline to end of study (EOS) in HAM-D total score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to relapse</measure>
    <time_frame>12 months</time_frame>
    <description>The time to new intervention for an emerging mood episode</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Major Depressive Disorders</condition>
  <arm_group>
    <arm_group_label>Clinical features and medication</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A group patients with significant high risk of clinical features and medications.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Psycho-social</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A group patients with significant high risk of psycho-social problems.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>immunology</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A group patients with significant high risk of immune disturbance.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Laboratory abnormality</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A group patients with significant high risk of Laboratory abnormalities.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comorbidity</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A group patients with physical or mental disorders comorbidities.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment as usual</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Control group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Clinical features and medication</intervention_name>
    <description>This group will be suggested to take optimize treatment according to Chinese treatment guidelines.</description>
    <arm_group_label>Clinical features and medication</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Psycho-social</intervention_name>
    <description>This group will be suggested to add on psychotherapy on medical treatment.</description>
    <arm_group_label>Psycho-social</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunology</intervention_name>
    <description>This group will be suggested to add on Omega-3 polyunsaturated fatty acid(PUFAs) on medical treatment.</description>
    <arm_group_label>immunology</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory abnormality</intervention_name>
    <description>This group will be suggested to more safety antidepressants.</description>
    <arm_group_label>Laboratory abnormality</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Comorbidity</intervention_name>
    <description>This group will be suggested to treat their comorbidities as well as treat MDD.</description>
    <arm_group_label>Comorbidity</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Treatment as usual</intervention_name>
    <description>Patients will accept routine treatments based on psychiatrist experience, not based on the relapse predict model.</description>
    <arm_group_label>Treatment as usual</arm_group_label>
    <other_name>Treatment as usual(TAU)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age from 18 to 65 years old;&#xD;
&#xD;
          -  Han Chinese;&#xD;
&#xD;
          -  Outpatient and inpatient patients;&#xD;
&#xD;
          -  Patients met Diagnostic and Statistical Manual of Mental Disorders(DSM-IV-TR) criteria&#xD;
             of bipolar I or II disorder, currently depressed, ascertained with the Mini&#xD;
             International Neuropsychiatric Interview (MINI)&#xD;
&#xD;
          -  Hamilton Depression Scale(HAM-D) total score≥17, HAM-D item 1 (depressed mood)&#xD;
             score≥2, and Young Mania Rating Scale(YMRS) total score≤10 at baseline;&#xD;
&#xD;
          -  Written informed consent was given;&#xD;
&#xD;
          -  Junior high school education and above, with enough audio-visual ability to accomplish&#xD;
             the visits;&#xD;
&#xD;
          -  Normally resident in one country and had a residential address, able to follow-up.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Bipolar disorder rapid cycling or mixed episode;&#xD;
&#xD;
          -  Experienced DSM-IV-TR axis I disorders in the 6 months prior to randomization;&#xD;
&#xD;
          -  Severe personality disorder, metal retardation, anorexia/bulimia nervosa;&#xD;
&#xD;
          -  Actively suicide ascertained by research psychiatrist or HAM-D item 3&#xD;
             score≥3(suicidality);&#xD;
&#xD;
          -  Female patients who were pregnant, planning to be pregnant or breast feeding;&#xD;
&#xD;
          -  Severe medical or neurological problems.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jun Chen, M.D., Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Mental Health Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jun Chen, M.D., Ph.D</last_name>
    <phone>021-34773367</phone>
    <email>doctorcj2010@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jia Huang, Master</last_name>
    <phone>13750892815</phone>
    <email>kittyhj_2000@aliyun.com</email>
  </overall_contact_backup>
  <verification_date>October 2016</verification_date>
  <study_first_submitted>October 20, 2016</study_first_submitted>
  <study_first_submitted_qc>October 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2016</study_first_posted>
  <last_update_submitted>October 25, 2016</last_update_submitted>
  <last_update_submitted_qc>October 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MDD</keyword>
  <keyword>big data analytics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

